Novartis Argentina When we met with Javier Lombar at IMS Argentina, he was explaining how a lot of multinational companies are using Argentina as a regional base of operations. Novartis is a prime example of this. Could you explain how Novartis operates in a Latin American context, and what role the Argentinean…
Genzyme (Shanghai) In 2006, Genzyme’s global CEO, Henri Termeer, said he is “personally very interested in China” and that he expects the company to build a capable infrastructure in ten years. We’re now 30% closer to the deadline. How has this deep commitment to China resulted in developments in the country and…
Biogen Idec - China You have been here in China for about a year. What were your assumptions about China before you arrived and were things more or less what you thought they would be or were you surprised about the reality on the ground? We conducted extensive research and scouting before setting up…
SinoGenoMax SinoGenoMax was founded in 1998 with the purpose of participating in the Human Genome Project. Could you give us an overview of the company’s activities since then and the transformation of the company over the past 11 years? SinoGenoMax was initially incorporated in 1998 as a joint investment between the…
Agendia Agendia has experienced remarkable growth in the seven years since you founded the company. In 2009 you expanded the company’s Amsterdam facilities and, in 2010, you doubled the size of its U.S. facilities. Why this drastic expansion, especially over the last two years? Agendia continues to grow at a rapid…
Celgene As a biopharmaceutical company, how have the PBS reforms affected Celgene? Celgene looks at the PBS reforms more positively than negatively. As a company with a smaller product portfolio of predominantly innovative medicines in haematology and oncology, it makes sense that the government looks to cut costs in the generic…
Generic Medicines Industry Association To begin, would you please introduce GMIA to Pharmaceutical Executive readers? The GMIA is an industry organization. Its six members are: Alphapharm, Apotex, Genepharm, Hospira, Sandoz and Sigma. The GMiA is the lobby group for the generic medicines industry in Australia, working with all relevant stakeholders, such as government, prescribers,…
Amgen Australia What impact have the PBS reforms had on Amgen in Australia? From a company perspective, biotechnology companies exist in a competitive space. They have predominantly niche medicines with significant competitive advantages and tend to be on their own in a certain clinical space and treatment paradigm. Amgen sells very few…
Genzyme Australia What impact will the recent PBS reforms have on Genzyme’s operations in Australia? Genzyme is different in terms of its focus on rare & unmet medical needs, so most of the company’s products, given they are targeted therapies, are not reimbursed through the PBS, but through other government funding mechanisms.…
Argentina SA Baxter Do you think this is a good moment for the Argentinean pharmaceutical industry to have international exposure? Indeed it is attractive, but we should keep the long term objectives on perspective. It is a stable and interesting market for multinational companies, as long as they can grasp the dynamics of…
Biogen Idec Argentina Biogen Idec’s arrival in Argentina has been very recent. Could you explain to our readers why the time was right to take back your licences and to set up in Argentina? Biogen Idec has a worldwide expansion strategy. Two years ago, the company decided to establish its own affiliates in…
Roche Argentina Argentina was home to Roche´s first Latin American subsidiary. Today, how important is Argentina for Roche worldwide? Argentina will become this year the third affiliate –after Brazil and Mexico-in terms of sales in Latin America, which of course makes it an important country for the Roche business, from a regional…
See our Cookie Privacy Policy Here
